Compare · CBLI vs OABI
CBLI vs OABI
Side-by-side comparison of Cleveland BioLabs, Inc. (CBLI) and OmniAb Inc. (OABI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLI and OABI operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- OABI carries a market cap of $736.6M.
- OABI has hit the wire 5 times in the past 4 weeks while CBLI has been quiet.
- OABI has more recent analyst coverage (5 ratings vs 0 for CBLI).
- Company
- Cleveland BioLabs, Inc.
- OmniAb Inc.
- Price
- -
- -
- Market cap
- -
- $736.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2006
- 2021
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 5
Latest CBLI
- SEC Form 4: Barbarick Steve K was granted 60,000 shares
- SEC Form 4: Verny Lea was granted 60,000 shares
- SEC Form DEF 14A filed by Cleveland BioLabs, Inc.
- SEC Form 4: Markvicka Taunia was granted 100,000 shares
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Cleveland BioLabs, Inc.
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest OABI
- Director Love Steven converted options into 13,334 shares, increasing direct ownership by 15% to 105,000 units (SEC Form 4)
- SEC Form 10-Q filed by OmniAb Inc.
- OmniAb Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights
- OmniAb to Participate in Upcoming Investor Conferences in November
- OmniAb to Report Third Quarter 2026 Financial Results on October 30
- OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst Day
- OmniAb to Host Investor & Analyst Day on October 6, 2026
- OmniAb to Participate in Upcoming Investor Conferences
- OmniAb Raises 2026 Financial Guidance